Health Tech Capitol | FluGen starts tests of a new influenza vaccine on humans
15409
post-template-default,single,single-post,postid-15409,single-format-standard,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

FluGen starts tests of a new influenza vaccine on humans

27 Jul FluGen starts tests of a new influenza vaccine on humans

Posted at 09:13h in Uncategorized by
0 Likes

FluGen, a Madison company developing a novel influenza vaccine, is starting its first round of human tests.

Phase 1 clinical trials of RedeeFlu began this week in Kansas City, Kansas, and will involve 96 healthy adults between 18 and 49 years old.

The vaccine, sprayed into a patient’s nose, is expected to provide protection against the main strains of flu and variations that evolve over the flu season.

“If the pre-clinical models prove true, it will work better than any vaccine in the market and it will work in more situations than any vaccine in the market today,” said Paul Radspinner, president and CEO of FluGen. “And that’s going to save lives.”

Read more at the Wisconsin State Journal

No Comments

Sorry, the comment form is closed at this time.